Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.

Journal of cancer research and clinical oncology

Arnold S, Kortland J, Maltseva DV, Nersisyan SA, Samatov TR, Lezius S, Tonevitsky AG, Milde-Langosch K, Wicklein D, Schumacher U, Stürken C.
PMID: 34693476
J Cancer Res Clin Oncol. 2021 Oct 24; doi: 10.1007/s00432-021-03812-2. Epub 2021 Oct 24.

PURPOSE: The transcription factor Fra-2 affects the invasive potential of breast cancer cells by dysregulating adhesion molecules in vitro. Previous results suggested that it upregulates the expression of E- and P-selectin ligands. Such selectin ligands are important members of...

Cite
Arnold S, Kortland J, Maltseva DV, et al. Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer. J Cancer Res Clin Oncol. 2021;doi: 10.1007/s00432-021-03812-2.
Arnold, S., Kortland, J., Maltseva, D. V., Nersisyan, S. A., Samatov, T. R., Lezius, S., Tonevitsky, A. G., Milde-Langosch, K., Wicklein, D., Schumacher, U., & Stürken, C. (2021). Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer. Journal of cancer research and clinical oncology, . https://doi.org/10.1007/s00432-021-03812-2
Arnold, Sabrina, et al. "Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer." Journal of cancer research and clinical oncology vol. (2021). doi: https://doi.org/10.1007/s00432-021-03812-2
Arnold S, Kortland J, Maltseva DV, Nersisyan SA, Samatov TR, Lezius S, Tonevitsky AG, Milde-Langosch K, Wicklein D, Schumacher U, Stürken C. Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer. J Cancer Res Clin Oncol. 2021 Oct 24; doi: 10.1007/s00432-021-03812-2. Epub 2021 Oct 24. PMID: 34693476.
Copy Download .nbib Format: NLM
Loss of .

Oncotarget

Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.
PMID: 29137324
Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.

BACKGROUND: Approximately 20-25% of ovarian cancers are attributable to germline or somatic METHODS: Tumor tissue from 76 patients with primary and 48 patients with platinum-sensitive recurrent high-grade ovarian cancer was collected. In a subgroup of 12 patients, 'paired' tumor...

Cite
Prieske K, Prieske S, Joosse SA, et al. Loss of . Oncotarget. 2017;8(47):83063-83074doi: 10.18632/oncotarget.20945.
Prieske, K., Prieske, S., Joosse, S. A., Trillsch, F., Grimm, D., Burandt, E., Mahner, S., Schmalfeldt, B., Milde-Langosch, K., Oliveira-Ferrer, L., & Woelber, L. (2017). Loss of . Oncotarget, 8(47), 83063-83074. https://doi.org/10.18632/oncotarget.20945
Prieske, Katharina, et al. "Loss of ." Oncotarget vol. 8,47 (2017): 83063-83074. doi: https://doi.org/10.18632/oncotarget.20945
Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L. Loss of . Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10. PMID: 29137324; PMCID: PMC5669950.
Copy Download .nbib Format: NLM
Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function.

Molecular and clinical oncology

VON Bülow C, Oliveira-Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K.
PMID: 26623052
Mol Clin Oncol. 2015 Sep;3(5):1067-1072. doi: 10.3892/mco.2015.593. Epub 2015 Jul 01.

Cadherin-11 (CDH11, OB-cadherin) is a mesenchymal cadherin found to be upregulated in various types of tumors and implicated in tumor progression and metastasis. In order to determine the role of CDH11 expression in ovarian tumors, we performed a combined...

Cite
VON Bülow C, Oliveira-Ferrer L, Löning T, et al. Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Mol Clin Oncol. 2015;3(5):1067-1072doi: 10.3892/mco.2015.593.
VON Bülow, C., Oliveira-Ferrer, L., Löning, T., Trillsch, F., Mahner, S., & Milde-Langosch, K. (2015). Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Molecular and clinical oncology, 3(5), 1067-1072. https://doi.org/10.3892/mco.2015.593
VON Bülow, Charlotte, et al. "Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function." Molecular and clinical oncology vol. 3,5 (2015): 1067-1072. doi: https://doi.org/10.3892/mco.2015.593
VON Bülow C, Oliveira-Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K. Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. Mol Clin Oncol. 2015 Sep;3(5):1067-1072. doi: 10.3892/mco.2015.593. Epub 2015 Jul 01. PMID: 26623052; PMCID: PMC4534870.
Copy Download .nbib Format: NLM
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.

BMC cancer

Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching PA, Rüschoff J, Stickeler E, Henke RP, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne CH, Marmé F, Schumacher U, Loibl S, Müller V.
PMID: 34526003
BMC Cancer. 2021 Sep 15;21(1):1024. doi: 10.1186/s12885-021-08754-z.

No abstract available.

Cite
Stürken C, Möbus V, Milde-Langosch K, et al. Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC Cancer. 2021;21(1):1024doi: 10.1186/s12885-021-08754-z.
Stürken, C., Möbus, V., Milde-Langosch, K., Schmatloch, S., Fasching, P. A., Rüschoff, J., Stickeler, E., Henke, R. P., Denkert, C., Hanker, L., Schem, C., Vladimirova, V., Karn, T., Nekljudova, V., Köhne, C. H., Marmé, F., Schumacher, U., Loibl, S., & Müller, V. (2021). Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC cancer, 21(1), 1024. https://doi.org/10.1186/s12885-021-08754-z
Stürken, Christine, et al. "Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer." BMC cancer vol. 21,1 (2021): 1024. doi: https://doi.org/10.1186/s12885-021-08754-z
Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching PA, Rüschoff J, Stickeler E, Henke RP, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne CH, Marmé F, Schumacher U, Loibl S, Müller V. Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC Cancer. 2021 Sep 15;21(1):1024. doi: 10.1186/s12885-021-08754-z. PMID: 34526003; PMCID: PMC8442450.
Copy Download .nbib Format: NLM
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.

OncoTargets and therapy

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V.
PMID: 25506225
Onco Targets Ther. 2014 Nov 28;7:2205-13. doi: 10.2147/OTT.S65344. eCollection 2014.

BACKGROUND: Protein levels of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) determined by enzyme-linked immunosorbent assay from fresh-frozen tumor tissue have been evaluated as prognostic factors in prospectively randomized trials in breast cancer. However, the role of uPA...

Cite
Witzel I, Milde-Langosch K, Schmidt M, et al. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther. 2014;7:2205-13doi: 10.2147/OTT.S65344.
Witzel, I., Milde-Langosch, K., Schmidt, M., Karn, T., Becker, S., Wirtz, R., Rody, A., Laakmann, E., Schütze, D., Jänicke, F., & Müller, V. (2014). Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. OncoTargets and therapy, 72205-13. https://doi.org/10.2147/OTT.S65344
Witzel, Isabell, et al. "Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer." OncoTargets and therapy vol. 7 (2014): 2205-13. doi: https://doi.org/10.2147/OTT.S65344
Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther. 2014 Nov 28;7:2205-13. doi: 10.2147/OTT.S65344. eCollection 2014. PMID: 25506225; PMCID: PMC4259258.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries